Strides Pharma Science Limited (STAR)

Loading page…

Strides Pharma Science Limited (STAR) · mywealthgrid

About

Strides Pharma Science Limited is a mid-cap pharmaceutical company with a market capitalisation of ₹8,923 Cr. The company generates consolidated quarterly revenue of approximately ₹1,200–1,300 Cr with operating profit margins of 18–19%, positioning it as a significant player in the Indian pharmaceuticals sector. Strong dividend history and a 1-year return of 21.23% reflect consistent operational performance and investor confidence.

Face value: ₹10

Market cap

₹10,002 Cr

P/E

16.3×

P/B

3.2×

Dividend yield

0.5%

ROE

19.7%

ROCE

23.3%

Debt / equity

0.54

OPM

19%

EPS (TTM)

₹66.6

Book value

₹337.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Quarterly net profit volatility ranges from ₹208 Cr (Dec 2025) to ₹129 Cr (Mar 2026) within a 6-month period — verify exposure to batch cycles, product concentration, or seasonal demand
Standalone OPM of 10–14% significantly trails consolidated OPM of 18–19%, suggesting structural cost or revenue-mix disadvantages — verify origin and reversibility
FII concentration at 28.39% (Jun 2026) combined with DII at 15.41% represents 43.8% institutional ownership — verify free float depth and liquidity during volatility
D/E ratio of 0.54; verify debt maturity profile, capex intensity, and covenant flexibility

Generated analysis · source review pending

Growth drivers

Consolidated revenue stable at ₹1,200–1,323 Cr per quarter across recent periods; verify if driven by volume gains, pricing, or product mix improvements
OPM of 19.04% reported alongside historical quarterly consolidated margins of 18–19% suggests margin sustainability; verify cost inflation hedges and pricing strategy
Margin convergence potential between standalone (10–14% OPM) and consolidated (18–19% OPM) segments could improve earnings without revenue growth; verify segment rationalization or integration plans
ROE of 19.66% and consistent dividend distribution (most recent Jul 2026) indicate robust cash generation; verify capex requirements and payout sustainability

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹1,084.8-7.5%1Y

Quick read

rule-based

Pros

+Strong return on equity of 56.7% (3-yr avg)
+High return on capital employed of 20.4%
+Profit CAGR of 15.7% over the last 5 years

Cons

−Modest revenue growth of 7.9% a year over the last 5 years
−Low dividend payout of 7.5% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

65/100

Business quality: 53
Growth: 66
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MICROCAP 250 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	2,839	3,012	2,752	3,316	3,070	3,688	4,051	4,565	4,859
COGS	—	1,379	1,466	1,122	1,333	1,502	1,627	1,641	1,980	1,959
Gross profit	—	1,461	1,546	1,629	1,983	1,568	2,062	2,411	2,585	2,900
	—	1,081	1,139	1,221	1,446	1,699	1,917	1,843	1,781	1,974
	—	380	406	409	537	-131	145	568	805	926
OPM %	—	13.4%	13.5%	14.9%	16.2%	-4.3%	3.9%	14%	17.6%	19.1%
Depreciation	73	154	172	174	206	233	243	221	192	202
Interest	—	196	205	156	150	177	261	314	249	179
	18	661	314	-37	109	-112	92	-95	3,311	124
Profit before tax	—	690	343	42	289	-653	-268	-63	3,675	669
Tax	—	10	13	11	32	-178	-55	32	78	94
Tax %	—	1.4%	3.8%	27%	10.9%	-27.3%	-20.7%	50.4%	2.1%	14.1%
	0	680	330	31	258	-474	-212	-94	3,598	575
PAT margin %	69.2%	24%	11%	1.1%	7.8%	-15.5%	-5.8%	-2.3%	78.8%	11.8%
EPS (₹)	—	73.8	36.3	4.1	30	-51.3	-22.5	-7.8	390.5	60.3
EPS adjusted (₹)	0	73.9	36.3	4.1	29.9	-51.3	-22.4	-7.7	389.9	60.3
	—	2.7%	8.3%	344.8%	8.3%	—	—	—	1%	8.3%
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	60	89	89	90	90	90	90	90	92	92	92
Reserves	1,096	2,659	2,664	2,559	2,438	2,687	2,269	2,122	2,034	2,460	3,015
Minority interest	14	134	134	153	67	37	24	—	—	35	42
	456	3,032	3,032	3,146	1,833	2,103	2,792	2,774	2,415	1,796	1,669
	855	2,191	2,355	2,032	1,724	2,098	1,801	1,652	1,300	1,667	2,109
Total equity & liabilities	2,481	8,105	8,274	7,980	6,152	7,015	6,976	6,638	5,840	6,049	6,927
	624	2,909	3,078	3,570	1,779	2,151	2,333	2,298	1,853	1,888	2,100
CWIP	112	205	205	100	148	228	56	48	80	100	161
Investments	668	1,525	1,525	702	549	766	554	502	315	420	292
	1,076	3,467	3,467	3,608	3,676	3,871	4,033	3,789	3,592	3,641	4,374
Total assets	2,481	8,105	8,274	7,980	6,152	7,015	6,976	6,638	5,840	6,049	6,927

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs.

Source XBRL ↗

Latest reported period · 31 Mar 2024 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities
Pharmaceutical business	4,051.12	319.44	—	3,768.05
Bio-pharmaceutical business	0	-121.93	—	0

SegmentFigure

Bio-pharmaceutical business · revenue

₹ crore by fiscal year

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	51.3%	59.2%	59.8%	51.1%	55.9%	59.5%	56.6%	59.7%
EBITDA margin %	15.1%	18.8%	19.2%	-0.7%	11.7%	18.4%	17.6%	19%
EBIT margin %	9.4%	12.4%	12.9%	-8.2%	5.1%	12.9%	13.4%	14.9%
PAT margin %	11%	1.1%	7.8%	-15.5%	-5.8%	-2.3%	78.8%	11.8%
Working capital
Receivable days	120	124	122	144	129	103	96	97
Inventory days	218	254	329	285	257	251	236	305
Payable days	1	6	311	260	220	189	190	244
NWC days	336	372	140	168	165	164	141	157
Leverage
Current ratio	1.15	0.93	1.03	0.99	1.05	1.03	1.2	1.25
Debt to EBITDA	6.92	3.55	3.31	—	6.45	3.25	2.24	1.8
Debt to equity	1.19	0.73	0.76	1.18	1.25	1.14	0.7	0.54
Interest coverage	1.6	2.5	3.2	-0.7	1.1	1.8	2.7	4.9
Asset turnover	0.38	0.45	0.47	0.44	0.56	0.69	0.75	0.7
Return ratios
Return on assets %	4.1%	0.5%	3.7%	-6.8%	-3.2%	-1.6%	59.5%	8.3%
Return on capital employed %	6.3%	8.9%	12.2%	-3.1%	7.7%	17%	20.9%	23.3%
Return on equity %	12.5%	1.2%	9.3%	-20.1%	-9.6%	-4.4%	141%	18.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	27.78%	27.39%	25.88%	25.86%	25.84%	26.82%	28.3%	28.3%	27.86%	27.86%	27.91%	27.91%
	17.25%	19.45%	24.57%	26.71%	30.08%	28.48%	28.32%	28.02%	28.51%	29.52%	28.68%	28.39%
	19.9%	19.41%	18.04%	18.56%	18.24%	16.92%	13.72%	13.3%	12.98%	13.02%	14.45%	15.41%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0.01%	0.01%	0.01%	0.01%
	35.07%	33.75%	31.51%	28.87%	25.84%	27.78%	29.66%	30.38%	30.64%	29.59%	28.95%	28.28%
No. of shareholders	—	—	—	—	—	—	—	—	91,206	85,589	86,616	94,850

Promoter holding up 0.13 percentage points since Sep 2023.

40 deals · 10 Dec 2021 – 28 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
28 Aug 2026	ARUN KUMAR PILLAI	Block	NSE	Buy	10,00,000	₹990.00	₹99.00 Cr
28 Aug 2026	SBI LIFE INSURANCE CO.LTD.	Block	NSE	Sell	10,00,000	₹990.00	₹99.00 Cr
28 Aug 2026	SBI LIFE INSURANCE CO.LTD.	Bulk	NSE	Sell	10,00,000	₹990.00	₹99.00 Cr
28 Aug 2026	ARUN KUMAR PILLAI	Bulk	NSE	Buy	10,00,000	₹990.00	₹99.00 Cr
31 Oct 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	5,78,738	₹938.69	₹54.33 Cr
31 Oct 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	5,78,738	₹937.22	₹54.24 Cr
22 Jan 2025	AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED	Bulk	NSE	Buy	5,18,350	₹558.88	₹28.97 Cr
9 Feb 2024	AMANSA HOLDING PRIVATE LTD.	Bulk	BSE	Buy	11,40,301	₹713.00	₹81.30 Cr
9 Feb 2024	BAJAJ FINANCE LIMITED	Bulk	BSE	Sell	8,04,629	₹713.00	₹57.37 Cr
9 Feb 2024	BAJAJ FINANCE LIMITED	Block	BSE	Sell	5,63,829	₹713.00	₹40.20 Cr

1–10 of 40

1 / 4

Mr. Arun Kumar PillaiNon-Executive - Non Independent Director-Chairperson related to Promoter
Mrs. Kausalya SanthanamNon-Executive - Independent Director
Mrs. Mukta AroraNon-Executive - Independent Director
Mr. Homi R KhusrokhanNon-Executive - Independent Director
Mr. Ameet Pratapsinh HarianiNon-Executive - Independent Director
Mr. Subir ChakrabortyNon-Executive - Independent Director
Mr. Badree KomandurExecutive Director-CEO-MD
Mr. Aditya Arun KumarNon-Executive - Non Independent Director
Mr. Venkata Seetharama Raju PakalapatiExecutive Director
Mr. Ramaraju PVSChief Operating Officer
Mr. Vikesh KumarChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 3 fund houses

Held by these funds

0.99%

of the company's equity

All mutual funds

8.73%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

5 schemes · 3 fund houses

		Shares
Small Cap Fund	Axis Mutual Fund	7.35 L	75.34	0.24%	0.797%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	1.73 L	17.7	0.71%	0.187%	-3,780
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	1,820	0.19	0.42%	0.002%	+2
IB18-Groww Nifty Total Market Index Fund	Groww Mutual Fund	1,182	0.12	0.03%	0.001%	+6
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	197	0.02	0.03%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Jul 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

19

Final dividend31 Jul 2026 · ex-date₹5
Final dividend22 Jul 2025 · ex-date₹4
Final dividend9 Sept 2024 · ex-date₹2.5
Final dividend4 Aug 2023 · ex-date₹1.5
Final dividend5 Aug 2021 · ex-date₹2.5
Final dividend24 Jul 2020 · ex-date₹2
Interim dividend22 Aug 2019 · ex-date₹12
Final dividend19 Jul 2019 · ex-date₹3
Final dividend12 Sept 2018 · ex-date₹2
Dividend dividend7 Sept 2017 · ex-date₹4.5
Dividend dividend21 Jul 2016 · ex-date₹4
Dividend dividend22 Jul 2015 · ex-date₹3
Special dividend16 Oct 2014 · ex-date₹105
Dividend dividend1 Sept 2014 · ex-date₹5
Special dividend19 Dec 2013 · ex-date₹500
Dividend dividend30 May 2013 · ex-date₹2
Dividend dividend14 May 2012 · ex-date₹2
Dividend dividend18 May 2011 · ex-date₹1.5
Dividend dividend21 May 2010 · ex-date₹1.5

1

Board meeting to consider results31 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

19 announcementsExport CSV

11 Sept 2026, 9:47 pmCompany Update

Completion Of USFDA Inspection At The Company''s Formulations Facility At Alathur

General PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	51.3%	59.2%	59.8%	51.1%	55.9%	59.5%	56.6%	59.7%
EBITDA margin %	15.1%	18.8%	19.2%	-0.7%	11.7%	18.4%	17.6%	19%
EBIT margin %	9.4%	12.4%	12.9%	-8.2%	5.1%	12.9%	13.4%	14.9%
PAT margin %	11%	1.1%	7.8%	-15.5%	-5.8%	-2.3%	78.8%	11.8%
Working capital
Receivable days	120	124	122	144	129	103	96	97
Inventory days	218	254	329	285	257	251	236	305
Payable days	1	6	311	260	220	189	190	244
NWC days	336	372	140	168	165	164	141	157
Leverage
Current ratio	1.15	0.93	1.03	0.99	1.05	1.03	1.2	1.25
Debt to EBITDA	6.92	3.55	3.31	—	6.45	3.25	2.24	1.8
Debt to equity	1.19	0.73	0.76	1.18	1.25	1.14	0.7	0.54
Interest coverage	1.6	2.5	3.2	-0.7	1.1	1.8	2.7	4.9
Asset turnover	0.38	0.45	0.47	0.44	0.56	0.69	0.75	0.7
Return ratios
Return on assets %	4.1%	0.5%	3.7%	-6.8%	-3.2%	-1.6%	59.5%	8.3%
Return on capital employed %	6.3%	8.9%	12.2%	-3.1%	7.7%	17%	20.9%	23.3%
Return on equity %	12.5%	1.2%	9.3%	-20.1%	-9.6%	-4.4%	141%	18.5%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
11 Sept 2026, 9:47 pm	Company Update General	Completion Of USFDA Inspection At The Company''s Formulations Facility At Alathur	PDF
19 Aug 2026, 7:37 pm	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release	PDF
18 Aug 2026, 4:01 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
14 Aug 2026, 5:08 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
3 Aug 2026, 5:24 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
1 Aug 2026, 4:29 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
31 Jul 2026, 7:32 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	PDF
31 Jul 2026, 12:44 pm	Company Update Investor Presentation	Announcement under Regulation 30 (LODR)-Investor Presentation	PDF

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	73	288	187	60	205	481	-258	44	701	684	703
	-2,225	-687	583	-148	1,306	-521	-119	302	-150	-90	-173
	2,944	338	-1,016	194	-1,709	-16	421	-214	-693	-643	-453
Net cash flow	792	-60	-246	106	-199	-55	45	133	-143	-48	76
Free cash flow	—	—	—	—	—	184	-401	-51	583	442	280
CFO / Operating profit %	—	—	47.2%	13.2%	39.7%	75.8%	—	10.3%	94.3%	85.3%	75.9%

Strides Pharma Science Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Segment results

Bio-pharmaceutical business · revenue

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

19

1

Announcements

19

1

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Segment results

Bio-pharmaceutical business · revenue

Compounded sales growth

Compounded profit growth

Return on equity

Strides Pharma Science Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

Bio-pharmaceutical business · revenue

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends19

Board meetings1

Announcements

Dividends19

Board meetings1

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Segment results

Bio-pharmaceutical business · revenue

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

19

1

19

1